Market Overview
During the 24‑hour period ending at 05:34 PM Central Europe on Wednesday, 21 October 2026, Brainsway Ltd. (BWAY.TA) experienced a modest decline of 1.26 %, settling at approximately ILA 3,715 per share on the Tel Aviv Stock Exchange. The company’s share supply stands at 404.2 k, while its market capitalisation currently amounts to ILA 486.8 million. In the past day, roughly ILA 109.3 million of Brainsway stock changed hands, representing a moderate level of liquidity relative to the firm’s size.
Since the end of September, Brainsway’s share price has fallen 10.35 %, a decline that reflects broader market sentiment and recent sector‑specific developments. Over the past 200 trading days, the simple moving average has settled at ILA 4,250.7, providing a benchmark against which the current price may be gauged. Historically, the company’s valuation peaked at ILA 5,165 on 21 July 2026, while its 52‑week low was ILA 2,391 on 25 November 2025.
Peer Performance
In the same 24‑hour window, the performance of related stocks offers context for Brainsway’s trajectory:
| Company | Ticker | 24‑hr Change | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|---|
| Aryt Industries | ARYT.TA | +6.32 % | ILA 1,537 | ILA 519 mn | 5.52 |
| Gauzy | GAUZ | –4.86 % | USD 4.39 | USD 4.4 mn | – |
| Land Development Nimrodi Gro | ILDC.TA | 0 % | ILA 4,009 | ILA 522.2 mn | 6.49 |
| Silynxcom | SYNX | +8.44 % | USD 0.74 | USD 5 mn | – |
| Kamada | KMDA.TA | –99.67 % | ILA 7.84 | ILA 1.4 bn | 0.06 |
Aryt Industries’ positive swing and Silynxcom’s sharp rally contrast with the flat performance of Land Development Nimrodi Gro and the steep decline of Gauzy, underscoring the volatility that can affect companies within the same broader market segment.
Corporate Context
Brainsway Ltd. is a commercial‑stage medical device company headquartered in Israel, specializing in non‑invasive neuromodulation technologies for the treatment of major depressive disorder (MDD) and obsessive‑compulsive disorder (OCD). Since its initial public offering on 17 April 2019, the firm has expanded its product portfolio and established a global distribution network. Its official website, www.brainsway‑global.com , provides detailed information on its therapeutic offerings, clinical trials, and corporate governance.
The company’s recent trading activity may be viewed against a backdrop of evolving regulatory frameworks for neurostimulation devices, as well as intensifying competition in the mental‑health therapeutics arena. Investors will likely monitor future earnings reports, clinical milestone announcements, and any strategic partnerships that could influence Brainsway’s market position.
The information presented here is based on publicly available market data as of the stated cutoff date. It is intended for informational purposes only and does not constitute investment advice.
